Tonia J. Buchholz is our Executive Director of Clinical Science. She brings deep experience in early phase oncology trials and clinical development strategy, with 20+ years in the drug discovery and biotech industry. She previously held senior roles across small and large biopharmaceutical companies, including Celgene/BMS, CARGO Therapeutics, Protoeolix/Onyx, Graphite Bio, and Zai Labs. Her background spans protein degraders, immune-cell engagers, and gene and cell therapy assets, transitioning new assets into the clinical for acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia, and neuroendocrine carcinoma. Her biotech career began at Rigel Pharmaceuticals profiling Syk kinase inhibitors for use in immune disorders. Tonia studied protein-carbohydrate interactions in Biochemistry at the University of Wisconsin – Madison, and her PhD in Chemical Biology explored protein-protein interactions at the University of Michigan – Ann Arbor. Outside of work, Tonia enjoys traveling and hiking.
Tonia J. Buchholz
